Q1. Does your trust treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which trust do you refer DLBCL patients to?
Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)?
Q3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
a. R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
b. R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
c. Other immuno-chemotherapy
d. Other chemotherapy
e. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
f. Pola-BR (polatuzumab vedotin with rituximab and bendamustine) – any line of treatment
g. Pola-BR (polatuzumab vedotin with rituximab and bendamustine) – third-line treatment only
h. Tisagenlecleucel
i. Axicabtegene ciloleucel
j. Lisocabtagene maraleucel
Q4. In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other trusts for:
a. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
b. CAR-T therapy (Tisagenlecleucel, Axicabtegene ciloleucel, Lisocabtagene maraleucel)
Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part?
